Evidence map›Paper›PMID 26959385›Full record

ArticleCancer2016

Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

A Blythe Ryerson, Christie R Eheman, Sean F Altekruse, John W Ward, Ahmedin Jemal, Recinda L Sherman, S Jane Henley, Deborah Holtzman, Andrew Lake, Anne-Michelle Noone and 6 more

6 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 508 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
508citing papers in PubMed, 10 pooled it
81.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03452553 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin

TypeinterventionalSponsorBoston Scientific CorporationRan2018 to 2020Enrolled0ConditionsHepatocellular Carcinoma (HCC)ArmsLC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
NCT03895970 phase2completednot on this mapstarted 2019, after this paper: background citation

Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study

TypeinterventionalSponsorPeking Union Medical College HospitalRan2019 to 2021Enrolled32ConditionsLiver Neoplasm Malignant Primary, Cholangiocarcinoma, Combinational Immunotherapy, BiomarkerArmsLenvatinib plus Pembrolizumab
NCT04010071 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2020 to 2024Enrolled60ConditionsHepatobiliary Neoplasm, Liver Neoplasm, Biliary Tract NeoplasmsArmsaxitinib plus toripalimab
NCT05048017 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma: A Single Arm, Nonrandomized, Single Center Clinical Study

TypeinterventionalSponsorPeking Union Medical College HospitalRan2021 to 2025Enrolled20ConditionsHepatocellular Carcinoma, Regorafenib, PD-1 InhibitorArmsRegorafenib, PD-1 inhibitor
NCT06123416 completednot on this mapstarted 2019, after this paper: background citation

Emotion Regulation and Cancer Caregiving

Typeobservational_patient_registrySponsorStanford UniversityRan2019 to 2019Enrolled30ConditionsBreast Cancer, Cancer, Healthy, EmotionsArmsExpressive Writing
NCT06207864 narecruitingnot on this mapstarted 2022, after this paper: background citation

Participant Engagement - Cancer Genome Sequencing (PE-CGS) Research Center: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

TypeinterventionalSponsorNew Mexico Cancer Research AllianceRan2022 to 2030Enrolled1,001ConditionsMalignant NeoplasmArmsBiospecimen Collection, Return of Results, Survey Administration
3 · Its place in the literature

Who cites it

508 citing papers in PubMed, 10 syntheses or guidelines pooled it, 935 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  13. Lumped parameter modeling of changes in liver hemodynamics due to cirrhosis.Biomechanics and modeling in mechanobiology · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

448 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

A Blythe RyersonDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Christie R EhemanDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Sean F AltekruseDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
John W WardDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Ahmedin JemalSurveillance Research Program, American Cancer Society, Atlanta, Georgia.
Recinda L ShermanNorth American Association of Central Cancer Registries, Springfield, Illinois.
S Jane HenleyDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Deborah HoltzmanDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Andrew LakeInformation Management Services, Inc., Rockville, Maryland.
Anne-Michelle NooneDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Robert N AndersonDivision of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland.
Jiemin MaSurveillance Research Program, American Cancer Society, Atlanta, Georgia.
Kathleen N LyDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kathleen A CroninDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Lynne PenberthyDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Betsy A KohlerNorth American Association of Central Cancer Registries, Springfield, Illinois.
National Cancer Institute · USNational Center for Chronic Disease Prevention and Health Promotion · USAmerican Cancer Society · USCenters for Disease Control and Prevention · USNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · USNorth American Association of Central Cancer Registries · USInformation Management Services · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundAnnual updates on cancer occurrence and trends in the United States are provided through an ongoing collaboration among the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR). This annual report highlights the increasing burden of liver and intrahepatic bile duct (liver) cancers.

methodsCancer incidence data were obtained from the CDC, NCI, and NAACCR; data about cancer deaths were obtained from the CDC's National Center for Health Statistics (NCHS). Annual percent changes in incidence and death rates (age-adjusted to the 2000 US Standard Population) for all cancers combined and for the leading cancers among men and women were estimated by joinpoint analysis of long-term trends (incidence for 1992-2012 and mortality for 1975-2012) and short-term trends (2008-2012). In-depth analysis of liver cancer incidence included an age-period-cohort analysis and an incidence-based estimation of person-years of life lost because of the disease. By using NCHS multiple causes of death data, hepatitis C virus (HCV) and liver cancer-associated death rates were examined from 1999 through 2013.

resultsAmong men and women of all major racial and ethnic groups, death rates continued to decline for all cancers combined and for most cancer sites; the overall cancer death rate (for both sexes combined) decreased by 1.5% per year from 2003 to 2012. Overall, incidence rates decreased among men and remained stable among women from 2003 to 2012. Among both men and women, deaths from liver cancer increased at the highest rate of all cancer sites, and liver cancer incidence rates increased sharply, second only to thyroid cancer. Men had more than twice the incidence rate of liver cancer than women, and rates increased with age for both sexes. Among non-Hispanic (NH) white, NH black, and Hispanic men and women, liver cancer incidence rates were higher for persons born after the 1938 to 1947 birth cohort. In contrast, there was a minimal birth cohort effect for NH Asian and Pacific Islanders (APIs). NH black men and Hispanic men had the lowest median age at death (60 and 62 years, respectively) and the highest average person-years of life lost per death (21 and 20 years, respectively) from liver cancer. HCV and liver cancer-associated death rates were highest among decedents who were born during 1945 through 1965.

conclusionsOverall, cancer incidence and mortality declined among men; and, although cancer incidence was stable among women, mortality declined. The burden of liver cancer is growing and is not equally distributed throughout the population. Efforts to vaccinate populations that are vulnerable to hepatitis B virus (HBV) infection and to identify and treat those living with HCV or HBV infection, metabolic conditions, alcoholic liver disease, or other causes of cirrhosis can be effective in reducing the incidence and mortality of liver cancer. Cancer 2016;122:1312-1337. © 2016 American Cancer Society.

Indexed as

Age DistributionAmerican Cancer SocietyCause of DeathCenters for Disease Control and Prevention, U.S.EthnicityFemaleHumansIncidenceLiver NeoplasmsMaleNational Cancer Institute (U.S.)NeoplasmsRacial GroupsRegistriesSex DistributionSex Factorsand End Results (SEER)cancerEpidemiologyincidenceliver cancermortalityNational Program of Cancer Registries (NPCR)North American Association of Central Cancer Registries (NAACCR)Surveillancesurvivaltrendsviral hepatitis

Identifiers

PMID26959385
PMCPMC4840031
OpenAlexW2294765885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.